These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20070039)

  • 1. Variation of substituents on pirarubicin for enhancing response to hepatocellular carcinoma and pattern recognition analysis to determine analogy to parent drug.
    Bartzatt RL
    Physiol Chem Phys Med NMR; 2008; 40():43-54. PubMed ID: 20070039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four hydrazide compounds that inhibit the growth of mycobacterium tuberculosis.
    Bartzatt R; Cirillo SL; Cirillo JD
    Physiol Chem Phys Med NMR; 2008; 40():55-65. PubMed ID: 20070040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma.
    Guiu B; Colin C; Cercueil JP; Loffroy R; Guiu S; Ferrant E; Jouve JL; Bonnetain F; Boulin M; Ghiringhelli F; Minello A; Hillon P; Bedenne L; Krause D; Chauffert B
    Am J Clin Oncol; 2009 Jun; 32(3):238-44. PubMed ID: 19349854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of homologous derivatives of cephalothin by multivariate methods for clinical efficacy.
    Bartzatt R
    Physiol Chem Phys Med NMR; 2006; 38(2):147-55. PubMed ID: 18472472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying pattern recognition methods and structure property correlations to determine drug carrier potential of nicotinic acid and analogize to dihydropyridine.
    Bartzatt R
    Eur J Pharm Biopharm; 2005 Jan; 59(1):63-71. PubMed ID: 15567303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
    Greish K; Nagamitsu A; Fang J; Maeda H
    Bioconjug Chem; 2005; 16(1):230-6. PubMed ID: 15656596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A computational model for anthracycline binding to DNA: tuning groove-binding intercalators for specific sequences.
    Cashman DJ; Kellogg GE
    J Med Chem; 2004 Mar; 47(6):1360-74. PubMed ID: 14998326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer agents for treatment of tumors in the central nervous system by correspondent substituent substitution and elucidation by pattern recognition methods.
    Bartzatt R
    Med Chem; 2012 Mar; 8(2):138-44. PubMed ID: 22385186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Aug; 443():1-321. PubMed ID: 12595920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases.
    Daruwalla J; Greish K; Malcontenti-Wilson C; Muralidharan V; Iyer A; Maeda H; Christophi C
    J Vasc Res; 2009; 46(3):218-28. PubMed ID: 18953175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.
    Ueno K; Miyazono N; Inoue H; Nishida H; Kanetsuki I; Nakajo M
    Cancer; 2000 Apr; 88(7):1574-81. PubMed ID: 10738215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
    Wiradharma N; Tong YW; Yang YY
    Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
    Hong RL; Tseng YL
    Cancer Chemother Pharmacol; 2003 May; 51(5):433-8. PubMed ID: 12736762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.